These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 2070136

  • 21. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Skin biopsies for early diagnosis and prognosis of graft-versus-host disease in recipients of allogeneic stem cells from blood or bone marrow.
    Heldal D, Brinch L, Evensen SA, Tjønnfjord GE, Aamodt G, Elgjo K, Sviland L.
    Bone Marrow Transplant; 2004 Aug 01; 34(4):345-50. PubMed ID: 15170163
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease.
    Schattenfroh NC, Hoffman RA, McCarthy SA, Simmons RL.
    Transplantation; 1995 Jan 27; 59(2):268-73. PubMed ID: 7839451
    [Abstract] [Full Text] [Related]

  • 26. Prognostic importance of histological and immunopathological assessment of skin and rectal biopsies in patients with GVHD.
    Sviland L, Pearson AD, Green MA, Eastham EJ, Hamilton PJ, Proctor SJ, Malcolm AJ.
    Bone Marrow Transplant; 1993 Mar 27; 11(3):215-8. PubMed ID: 8467285
    [Abstract] [Full Text] [Related]

  • 27. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M, Wettstein PJ, Korngold R.
    Transplantation; 1994 Apr 15; 57(7):1095-102. PubMed ID: 7909395
    [Abstract] [Full Text] [Related]

  • 28. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE.
    J Immunol; 1996 Dec 01; 157(11):4811-21. PubMed ID: 8943383
    [Abstract] [Full Text] [Related]

  • 29. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
    Leung AY, Kwok J, Lie AK, Chen P, Chen FE, Liang R.
    Haematologica; 2001 Jun 01; 86(6):652-6. PubMed ID: 11418376
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients.
    Epstein RJ, McDonald GB, Sale GE, Shulman HM, Thomas ED.
    Gastroenterology; 1980 Apr 01; 78(4):764-71. PubMed ID: 6986319
    [Abstract] [Full Text] [Related]

  • 32. Immunopathology of early graft-versus-host disease--a prospective study of skin, rectum, and peripheral blood in allogeneic and autologous bone marrow transplant recipients.
    Sviland L, Pearson AD, Green MA, Baker BD, Eastham EJ, Reid MM, Hamilton PJ, Proctor SJ, Malcolm AJ.
    Transplantation; 1991 Dec 01; 52(6):1029-36. PubMed ID: 1836284
    [Abstract] [Full Text] [Related]

  • 33. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.
    Yabe M, Yabe H, Hattori K, Shimizu T, Matsumoto M, Morimoto T, Yasuda Y, Inoue H, Kato S, Nishimura T.
    Bone Marrow Transplant; 1999 Jul 01; 24(1):29-34. PubMed ID: 10435731
    [Abstract] [Full Text] [Related]

  • 34. A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease.
    Faaij CM, Lankester AC, Spierings E, Hoogeboom M, Bowman EP, Bierings M, Révész T, Egeler RM, van Tol MJ, Annels NE.
    Br J Haematol; 2006 Jun 01; 133(5):538-49. PubMed ID: 16681643
    [Abstract] [Full Text] [Related]

  • 35. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP, Gratama JW, Lamers C, van Esser JW, Bolhuis RL, Cornelissen JJ.
    Bone Marrow Transplant; 1999 May 01; 23(10):1013-7. PubMed ID: 10373067
    [Abstract] [Full Text] [Related]

  • 36. Distinct TCRAV and TCRBV repertoire and CDR3 sequence of T lymphocytes clonally expanded in blood and GVHD lesions after human allogeneic bone marrow transplantation.
    Hirokawa M, Matsutani T, Saitoh H, Ichikawa Y, Kawabata Y, Horiuchi T, Kitabayashi A, Yoshioka T, Tsuruta Y, Suzuki R, Miura AB, Sawada K.
    Bone Marrow Transplant; 2002 Dec 01; 30(12):915-23. PubMed ID: 12476285
    [Abstract] [Full Text] [Related]

  • 37. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA, Passweg J, Kawanishi Y, Casper J, Flomenberg N, Baxter-Lowe LA.
    Bone Marrow Transplant; 1997 May 01; 19(10):1001-9. PubMed ID: 9169644
    [Abstract] [Full Text] [Related]

  • 38. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE.
    Bone Marrow Transplant; 1994 May 01; 13(5):571-5. PubMed ID: 7519937
    [Abstract] [Full Text] [Related]

  • 39. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Jansen J, Hanks S, Akard L, Martin M, Thompson J, Chang Q, Ash R, Garrett P, Figg F, English D.
    Bone Marrow Transplant; 1995 Feb 01; 15(2):271-8. PubMed ID: 7773217
    [Abstract] [Full Text] [Related]

  • 40. Differences between lymphocyte subsets, after allogeneic bone marrow transplantation, in patients who received tacrolimus and patients who received cyclosporin A.
    Fukuda H, Teshima H, Karasuno T, Hiraoka A, Nakamura H, Masaoka T.
    Int J Hematol; 2000 Jan 01; 71(1):70-4. PubMed ID: 10729997
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.